Rational design of SphK inhibitors using crystal structures aided by computer

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Sphingosine kinases (SphKs) phosphorylate sphingosine to sphingosine-1-phosphate (S1P), a crucial bioactive lipid.
• Dysregulation of SphKs and S1P signaling are implicated in diverse pathophysiological conditions.
• Targeting the S1P pathway presents a promising therapeutic strategy for numerous diseases.

Purpose of the Study:

• To review the structural characteristics and functional differences between SphK1 and SphK2 isoforms.
• To summarize the development of small molecule inhibitors targeting SphKs, particularly SphK1.
• To highlight recent advancements in SphK1/SphK2 selective inhibitors and the ongoing exploration of SphK2 structure.

Main Methods:

• Structural biology analysis of SphK1 co-crystal structures with inhibitors.
• Review of literature on SphK1 and SphK2 isoforms and their inhibitors.
• Comparative analysis of SphK1 and SphK2 structures and functions.

Main Results:

• Detailed examination of SphK1 crystal structures, including its unique Sph binding site.
• Identification of key structural differences and similarities between SphK1 and SphK2.
• Summary of progress in developing selective inhibitors for both SphK1 and SphK2.

Conclusions:

• Understanding SphK isoforms' structures is vital for designing effective S1P pathway inhibitors.
• SphK1 inhibitors are advancing, while SphK2 structure and inhibition remain areas of active research.
• Targeting SphKs offers a viable therapeutic avenue for diseases associated with S1P signaling dysregulation.